<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00195312</url>
  </required_header>
  <id_info>
    <org_study_id>6120K1-100</org_study_id>
    <nct_id>NCT00195312</nct_id>
  </id_info>
  <brief_title>Study Evaluating Vaccine in Adults With HIV</brief_title>
  <official_title>A Phase 1 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine Administered Alone or With Escalating Doses of IL-12 DNA or IL-15 DNA Molecular Adjuvants to HIV-1 Positive Adults Receiving Stable HAART.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn whether the study vaccine and the adjuvants(drugs
      that are used to help immune response) have an acceptable safety profile in treating
      individuals with HIV.

      A second purpose for this study is to understand how your immune system responds to the study
      vaccine with the adjuvants. Understanding these differences could be useful in several ways.
      First, it might help identify people whose disease is likely to respond to the study vaccine
      with the study adjuvants. Second, the information might be useful in developing other
      treatments for people whose disease does not respond to the study vaccine with the adjuvants.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of intramuscular administration of HIV-1 gag DNA vaccine (total of three doses) in individuals on stable HAART</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>intramuscular administration of HIV-1 gag DNA vaccine when administered with increasing dosage levels of IL-12 DNA following each vaccine dose (total of three doses) in individuals on stable HAART</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>intramuscular administration of HIV-1 gag DNA vaccine when administered with increasing dosage levels of IL-15 DNA following each vaccine dose (total of three doses) in individuals on stable HAART</measure>
  </primary_outcome>
  <enrollment type="Anticipated">91</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIV-1 gag DNA (formulated with bupivacaine)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IL-15 DNA (formulated with bupivacaine)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IL-12 DNA (formulated with bupivacaine)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sodium chloride injection USP (0.9%)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be HIV positive.

          -  Receiving stable HAART for a minimum of 6 consecutive months immediately before
             screening.

          -  CD4 T-cell count greater than 350 mm cubed/mL at time of screening and no reported CD4
             T-cell count less than 250 mm cubed/mL at any time before screening.

        Other Inclusions Apply

        Exclusion Criteria:

          -  Any chronic symptomatic infection other than HIV.

          -  History of diagnosed autoimmune disease (currently active or under control).

          -  Use of any prior HIV vaccine (prophylactic and/or therapeutic) within one year before
             or during screening (documented, unblinded placebo recipients from previous clinical
             trials may participate without this time restriction).

        Other Exclusions Apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Germany, MedinfoDEU@wyeth.com</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Sweden, MedInfoNord@wyeth.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>118 23</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>December 3, 2007</last_update_submitted>
  <last_update_submitted_qc>December 3, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2007</last_update_posted>
  <keyword>HIV</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

